+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Indication (Oncology, CNS, Cardiology), by Region, and Segment Forecasts, 2021-2028

  • ID: 5415597
  • Report
  • April 2021
  • Region: Global
  • 120 Pages
  • Grand View Research

FEATURED COMPANIES

  • Covance Inc.
  • ICON plc
  • IQVIA Holdings Inc.
  • MEDPACE HOLDINGS, INC.
  • Novartis
  • Novotech
The global cell and gene therapy clinical trials market size is expected to reach USD 45.4 billion by 2028. It is expected to expand at a CAGR of 22.3% from 2021 to 2028. Increasing funding, investments in research and development, and successful product launches are boosting the market growth.



Cell and gene therapies (CGTs) signify the next great movement of therapeutic innovation and have resulted in the development of promising therapies around the world. Although a few of the early therapies have got marketing approval in the U.S., there are numerous promising therapies in development across the world.

The market of cell and gene therapy has witnessed significant growth over the past few years with pharma firms partnering to create effective and accessible therapies for patients. As reported by PhRMA in 2019, there were 362 cell and gene therapies in clinical development in the U.S. representing a 20% increase from 2018. In addition, by the end of 2019, there were more than 1,000 cell and gene therapy clinical trials in the process including 452 gene-modified and cell-based immune-oncology, 352 gene therapies, 216 cell therapies, and 46 tissue engineering.

Besides, investment is rolling into companies of various types, ranging from startups to major acquisitions by significant biopharmaceutical companies. In 2019, 19 deals of M&A worth over USD 156 billion were completed. The largest of these was the acquisition of Celgene and its pipeline of numerous cell therapy assets by Bristol-Myers Squibb for USD 74 billion is expected to boost its participation in oncology treatments. Hence, representing a noteworthy increase since 2015, when M&A activities in these are totaled about USD 4 billion.

Cell And Gene Therapy Clinical Trials Market Report Highlights

  • By phase, the phase II segment held the largest share of over 50.0% in 2020 owing to the large number of therapies currently in development in phase II
  • Based on indication, the oncology segment held the largest share of 47.0% in 2020 as oncology alone contributed to 600 CGT clinical trials out of around 1,000
  • North America dominated the global market with a share of 48.3% in 2020. This is largely attributed to a large number of clinical trial activities in the U.S. and favorable government support
  • The Asia Pacific region is expected to expand at the fastest CAGR of 23.1% over the forecast period owing to the increasing number of biotechnology companies focusing on CGTs
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Covance Inc.
  • ICON plc
  • IQVIA Holdings Inc.
  • MEDPACE HOLDINGS, INC.
  • Novartis
  • Novotech
Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Phase
1.1.2 Indication
1.1.3 Regional Scope
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Abbreviations
1.9 Objectives
1.9.1 Objective - 1:
1.9.2 Objective - 2:
1.9.3 Objective - 3:
1.9.4 Objective - 4:

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights

Chapter 3 Cell & Gene Clinical Trials Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Ancillary market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 COVID-19 pandemic impact on clinical trial activity
3.3.1 Obstacles in clinical trials:
3.3.2 Disrupted clinical trials:
3.3.2.1 Companies with Phase I trial disruption
3.3.2.2 Companies with Phase 2 trial disruption
3.3.2.3 Companies with Phase 3 trial disruption
3.4 Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Growing interest in CGT
3.4.1.2 Favorable regulatory environment
3.4.1.3 Increasing R&D funding
3.4.2 Market Restraint Analysis
3.4.2.1 Recruitment obstacles
3.4.3 Industry Challenge
3.4.3.1 Creating a high-touch treatment center model
3.4.3.2 Collecting raw materials
3.4.3.3 Commercialization issues
3.4.4 Opportunity
3.4.4.1 Drug approval and a strong pipeline of cell & gene therapy
3.4.6 Trends in the CGT
3.4.7 Regulations
3.4.9 COVID-19 Impact on the industry:
3.4.9.1 Time-sensitive CGTs during the pandemic
3.5 Cell & Gene Therapy Clinical Trials Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 PESTEL Analysis
3.5.2.1 Political
3.5.2.2 Economic
3.5.2.3 Technological
3.5.3 Major Deals & Strategic Alliances Analysis

Chapter 4 Cell and Gene Therapy Clinical Trials Market: Phase Segment Analysis
4.1 Cell and Gene Therapy Clinical Trials: Market Share Analysis, 2020 & 2028
4.2 Phase I
4.2.1 Phase I market, 2016 - 2028 (USD Million)
4.3 Phase II
4.3.1 Phase II market, 2016 - 2028 (USD Million)
4.4 Phase III
4.4.1 Phase III market, 2016 - 2028 (USD Million)
4.5 Phase IV
4.5.1 Phase IV market, 2016 - 2028 (USD Million)

Chapter 5 Cell & Gene Therapy Clinical Trials Market: Indication Segment Analysis
5.1 Cell & Gene Therapy Clinical Trials: Market Share Analysis, 2020 & 2028
5.2 Oncology
5.2.1 Oncology market, 2016 - 2028 (USD Million)
5.3 Cardiovascular
5.3.1 Cardiovascular market, 2016 - 2028 (USD Million)
5.4 CNS
5.4.1 CNS market, 2016 - 2028 (USD Million)
5.5 Musculoskeletal
5.5.1 Musculoskeletal market, 2016 - 2028 (USD Million)
5.6 Infectious diseases
5.6.1 Infectious diseases market, 2016 - 2028 (USD Million)
5.7 Dermatology
5.7.1 Dermatology market, 2016 - 2028 (USD Million)
5.8 Endocrine, metabolic, genetic
5.8.1 Endocrine, metabolic, genetic market, 2016 - 2028 (USD Million)
5.9 Immunology & inflammation
5.9.1 Immunology & inflammation market, 2016 - 2028 (USD Million)
5.10 Ophthalmology
5.10.1 Ophthalmology market, 2016 - 2028 (USD Million)
5.11 Hematology
5.11.1 Hematology market, 2016 - 2028 (USD Million)
5.12 Gastroenterology
5.12.1 Gastroenterology market, 2016 - 2028 (USD Million)
5.13 Others
5.13.1 Others market, 2016 - 2028 (USD Million)

Chapter 6 Cell & Gene Therapy Clinical Trials Market: Regional Analysis
6.1 Cell and Gene Therapy Clinical Trials: Market Share Analysis, 2020 & 2028
6.2 North America
6.2.1 North America cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.2.3 Canada
6.2.3.1 Canada cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.3 Europe
6.3.1 Europe cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.3.2 U.K.
6.3.2.1 U.K. cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.3.3 Germany
6.3.3.1 Germany cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.3.4 France
6.3.4.1 France cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.3.5 Italy
6.3.5.1 Italy cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.3.6 Spain
6.3.6.1 Spain cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.4.2 India
6.4.2.1 India cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.4.3 Japan
6.4.3.1 Japan cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.4.4 China
6.4.4.1 China cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.4.5 Australia
6.4.5.1 Australia cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.4.6 South Korea
6.4.6.1 South Korea cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.5 Latin America
6.5.1 Latin America cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.5.4 Argentina
6.5.4.1 Argentina cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.5.5 Colombia
6.5.5.1 Colombia cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.6 MEA
6.6.1 MEA cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.6.3 Saudi Arabia
6.6.3.1 Saudi Arabia cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)
6.6.4 UAE
6.6.4.1 UAE cell & gene therapy clinical trials market, 2016 - 2028 (USD Million)

Chapter 7 Company Profiles
7.1 Company Profiles
7.1.1 ICON plc
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Service benchmarking
7.1.1.4 Strategic initiatives
7.1.2 IQVIA Holdings Inc.
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Service benchmarking
7.1.2.4 Strategic initiatives
7.1.3 PAREXEL International Corporation
7.1.3.1 Company overview
7.1.3.2 Service benchmarking
7.1.3.3 Strategic initiatives
7.1.4 Covance Inc.
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Service benchmarking
7.1.5 Syneos Health
7.1.5.1 Company overview
7.1.5.2 Financial performance
7.1.5.3 Service benchmarking
7.1.5.4 Strategic Initiatives
7.1.6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
7.1.6.1 Company overview
7.1.6.2 Financial performance
7.1.6.3 Service benchmarking
7.1.6.4 Strategic initiatives
7.1.7 MEDPACE HOLDINGS, INC.
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Service benchmarking
7.1.8 Novartis
7.1.8.1 Company overview
7.1.8.2 Financial Performance
7.1.8.3 Service benchmarking
7.1.8.4 Strategic initiatives
7.1.9 Novotech
7.1.9.1 Company overview
7.1.9.2 Service benchmarking
7.1.9.3 Strategic initiatives
7.1.10 Veristat, LLC
7.1.10.1 Company overview
7.1.10.2 Service benchmarking
7.1.10.3 Strategic initiatives

Chapter 8 Observation & Recommendations



List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Cell and Gene Therapy Clinical Trials Market, By Region 2016 - 2028 (USD Million)
Table 4 Global Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 5 Global Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 6 North America Cell and Gene Therapy Clinical Trials Market, By Country, 2016 - 2028 (USD Million)
Table 7 North America Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 8 North America Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 9 U.S. Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 10 U.S. Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 11 Canada Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 12 Canada Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 13 Europe Cell and Gene Therapy Clinical Trials Market, By Country, 2016 - 2028 (USD Million)
Table 14 Europe Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 15 Europe Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 16 U.K. Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 17 U.K. Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 18 Germany Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 19 Germany Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 20 France Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 21 France Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 22 Italy Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 23 Italy Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 24 Spain Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 25 Spain Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 26 Asia Pacific Cell and Gene Therapy Clinical Trials Market, By Country, 2016 - 2028 (USD Million)
Table 27 Asia Pacific Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 28 Asia Pacific Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 29 India Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 30 India Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 31 Japan Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 32 Japan Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 33 China Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 34 China Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 35 Australia Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 36 Australia Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 37 South Korea Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 38 South Korea Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 39 Latin America Cell and Gene Therapy Clinical Trials Market, By Country, 2016 - 2028 (USD Million)
Table 40 Latin America Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 41 Latin America Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 42 Brazil Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 43 Brazil Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 44 Mexico Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 45 Mexico Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 46 Argentina Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 47 Argentina Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 48 Colombia Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 49 Colombia Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 50 MEA Cell and Gene Therapy Clinical Trials Market, By Country, 2016 - 2028 (USD Million)
Table 51 MEA Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 52 MEA Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 53 South Africa Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 54 South Africa Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 55 Saudi Arabia Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 56 Saudi Arabia Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)
Table 57 UAE Cell and Gene Therapy Clinical Trials Market, By Phase, 2016 - 2028 (USD Million)
Table 58 UAE Cell and Gene Therapy Clinical Trials Market, By Indication, 2016 - 2028 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Cell and gene therapy clinical trials market: Market snapshot
Fig. 9 Cell and gene therapy clinical trials market: Market segmentation
Fig. 10 Cell and gene therapy clinical trials market Strategy framework
Fig. 11 Cell and gene therapy clinical trials market driver impact
Fig. 12 Cell and gene therapy clinical trials market restraint impact
Fig. 13 Cell and gene therapy clinical trials market porter’s five forces analysis
Fig. 14 Cell and gene therapy clinical trials market PESTEL analysis
Fig. 15 Cell and gene therapy clinical trials market: Phase segment dashboard
Fig. 16 Cell and gene therapy clinical trials market: Phase movement Analysis
Fig. 17 Phase I estimates and forecast, 2016 - 2028 (USD Million)
Fig. 18 Phase II estimates and forecast, 2016 - 2028 (USD Million)
Fig. 19 Phase III estimates and forecast, 2016 - 2028 (USD Million)
Fig. 20 Phase IV estimates and forecast, 2016 - 2028 (USD Million)
Fig. 21 Cell and gene therapy clinical trials market: Indication segment dashboard
Fig. 22 Cell and gene therapy clinical trials market: Indication movement analysis
Fig. 23 Oncology market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 24 Cardiology market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 25 CNS market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 26 Musculoskeletal market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 27 Infectious diseases market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 28 Dermatology market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 29 Endocrine, metabolic, genetic market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 30 Immunology & inflammation market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 31 Ophthalmology market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 32 Hematology market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 33 Gastroenterology market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 34 Others market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 35 Global cell & gene therapy clinical trials market: Regional movement analysis
Fig. 36 Global cell & gene therapy clinical trials market: Regional outlook and key takeaways
Fig. 37 North America market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 38 U.S. market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 39 Canada market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 40 Europe market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 41 U.K. market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 42 Germany market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 43 France market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 44 Italy market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 45 Spain market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 46 Asia Pacific market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 47 China market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 48 Japan market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 49 India market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 50 Australia market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 51 South Korea market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 52 Latin America market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 53 Brazil market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 54 Mexico market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 55 Argentina market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 56 Colombia market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 57 Middle East and Africa market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 58 South Africa market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 59 Saudi Arabia market estimates and forecast, 2016 - 2028 (USD Million)
Fig. 60 UAE market estimates and forecast, 2016 - 2028 (USD Million)
Note: Product cover images may vary from those shown
  • ICON plc
  • IQVIA Holdings Inc.
  • PAREXEL International Corporation
  • Covance Inc.
  • Syneos Health
  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
  • MEDPACE HOLDINGS, INC.
  • Novartis
  • Novotech
  • Veristat, LLC
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll